Pre-market Movers For Aug 1 (XOM, PG, COP, CI, DTV, DELL, JCP, YELP, CTRP, HALO)

(RTTNews) - Gainers:

Procter & Gamble Co. (PG) is rising 2 percent to $82.00. The company's fourth quarter profit fell 48 percent from the prior year period, but its core earnings per share topped Street view. Net sales improved 2 percent and came above market view.

ConocoPhillips (COP) is rising 1 percent to $65.60. The company's second quarter profit declined from the last year quarter, but earnings per share, excluding items, topped Street view. The company also raised its full-year production guidance.

CIGNA Corp. (CI) is gaining 1 percent to $78.75 as its second quarter results were above Wall Street view. The company also raised its full-year 2013 earnings outlook.

Dell Inc. (DELL) is up more than 1 percent to $12.88.

J. C. Penney Company, Inc. (JCP) is up alomost 7 percent to $15.60 based on its clarification that CIT continues to factor and support deliveries from the company's suppliers. The company said it continues to have the support of all of its key vendors, who have maintained their shipments to the company. Yelp, Inc. (YELP) is surging 14 percent to $47.89 and Ctrip.com International, Ltd. (CTRP) is gaining 12 percent to $41.01 following the release of their quarterly results.

Decliners:

Exxon Mobil Corp. (XOM) is falling more than 1 percent to $92.61. The company's second quarter profit plunged from the year-ago quarter and missed Wall Street view. Meanwhile, both upstream and downstream earnings were higher then the prior year period. Total revenues and other income declined from the year-ago quarter, but managed to come above the consensus estimate.

DIRECTV (DTV) is down 5 percent to $60.00. The company's second quarter earnings declined from the same quarter a year earlier and were below analysts' expectation. Revenues rose about 7 percent, but marginally missed the consensus estimate.

Halozyme Therapeutics, Inc. (HALO) is plunging 18 percent to $6.90. The company announced that ViroPharma (VPHM) will be discontinuing their Phase 2 study of subcutaneous Cinryze with recombinant human hyaluronidase following discussions with the FDA's CBER division. The discontinuation of the study is a precaution related to the emergence of an unexpected incidence and titer of non-neutralizing anti-rHuPH20 antibodies in a number of patients with the formulation being used in this study.